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G protein-coupled receptors (GPCRs), which includes the gonadotropin-releasing hormone 
(GnRH) receptor (GnRHR), comprises the largest family of validated drug targets – more than 
half of all approved drugs derive their benefits by selective targeting of GPCRs. Most drugs 
in this class are either agonists or antagonists of GPCRs and high throughput screens have 
typically been designed and performed with a view toward identification of such compounds 
as lead drug candidates. This manuscript presents the case that valuable drugs which effect 
the trafficking of GPCRs may have been overlooked because pharmacoperones have been 
selected from existing screens that identify agonists and antagonists. A “gain of activity assay” 
is proposed; this assay relies on the expression of a mutant of the GnRHR that is known to 
be rescuable by pharmacoperone drugs, and which is restored to activity in their presence. 
Accordingly, “hits” are identified by the appearance of activity. The gene for the mutant is under 
control of tetracycline and may be prevented from being expressed. This is a valuable feature 
since it allows false positives to be identified. Such drugs will show apparent activity whether or 
not the mutant is expressed. This assay will enable identification of these drugs from chemical 
libraries and does not rely on their activity as agonists or antagonists.
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binding and effector coupling, but are recognized as misfolded 
by such general criteria, can be misrouted to the ER. Their rescue 
with pharmacoperones leads to proper folding, passage through 
the QCS, restoration to the proper site, and return of function.
In principle, the pharmacoperone rescue approach may apply to 
a diverse array of human diseases that result from protein  misfolding 
– among these are cystic fibrosis (misfolding of the cystic fibrosis 
transmembrane conductance regulator, a transporter class ion chan-
nel that transports chloride and thiocyanate ions; Dormer et al., 2001; 
Galietta et al., 2001; Zhang et al., 2003; Amaral, 2006), hypogonado-
tropic hypogonadism [HH, The gonadotropin-releasing hormone 
(GnRH) receptor (GnRHR); Ulloa-Aguirre et al., 2003], nephro-
genic diabetes insipidus (Morello and Bichet, 2001; Bernier et al., 
2004; Bichet, 2006), retinitis pigmentosa (rhodopsin; Noorwez et al., 
2004), hypercholesterolemia (LDL receptor), cataracts (crystallines; 
Benedek et al., 1999), neurodegenerative diseases (Huntington’s, 
Alzheimer’s, Parkinson’s; Heiser et al., 2000; Soto et al., 2000; Forloni 
et al., 2002; Permanne et al., 2002; Muchowski and Wacker, 2005), and 
particular cancers (Peng et al., 2003). In the case of certain proteins 
(e.g., the GnRHR, V2R, and rhodopsin), this approach has succeeded 
with a striking number of different mutants (Conn et al., 2007), 
supporting the view that pharmacoperones will become powerful 
weapons in our therapeutic arsenal (Conn et al., 2007).
It has also become clear that variable (but significant) amounts 
of even some wild-type (WT) GPCRs are misrouted (i.e., fre-
quently retained in the ER), apparently as a result of misfolding 
IntroductIon
Mutations in G protein-coupled receptors (GPCRs) are known 
to be responsible for over 30 disorders, including cancers, her-
itable obesity, and endocrine disease. Normally, nascent GPCRs 
are subjected to the stringent quality control system (QCS) of the 
endoplasmic reticulum (ER); this system consists of both protein 
chaperones that promote correct folding by catalyzing the folding 
process or may retain misfolded proteins. The QCS ensures that 
only correctly folded proteins enter the pathway leading to the 
plasma membrane (PM). Because of this, point mutations may 
result in the production of misfolded and disease-causing proteins 
that are unable to reach their functional destinations in the cell 
since they are retained by the QCS even though they may retain 
(or regain) function when properly trafficked.
The functional rescue of misfolded mutant receptors by small 
non-peptide molecules, originally screened from chemical libraries 
to serve as receptor antagonists, has now been demonstrated (Conn 
et al., 2007); these small molecules (pharmacological chaperones 
or “pharmacoperones”) serve as molecular templates, promoting 
correct folding, and allowing the mutants to pass the scrutiny of the 
QCS and be expressed at the PM (or, in some cases, other cellular 
loci) where they may function normally. It is important to note 
that the QCS is not protein-specific; it recognizes general aspects of 
misfolding (e.g., exposure of hydrophobic plates in aqueous envi-
ronments or unpaired sulfhydryl groups in cysteines), frequently 
with relatively low affinity. Accordingly, GPCRs that retain ligand 
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The human GnRHR, unlike the rat and mouse counterparts, 
appears “balanced” in its distribution between the PM and ER 
(Conn et al., 2006a,b), so much that about 50% of the human 
WT GnRHR (in cells transfected with the corresponding 
sequence) is retained in the ER and can be “rescued” by the 
approach described above. At first consideration this appears to 
be an inefficient use of newly synthesized protein; however, the 
strong and convergent evolutionary pressure for this suggests a 
regulatory advantage (Conn et al., 2006a,b; Ulloa-Aguirre et al., 
2006). This system offers the ability to examine the evolution 
of the QCS system since these receptors have been cloned from 
a wide range of animals (fish, birds, reptiles, many mammals, 
and multiple primates; Janovick et al., 2003b).
4. A great deal of information is also available regarding the cellu-
lar mechanism of action and trafficking of the GnRHR (Jennes 
et al., 2009) as is substantive information on the mechanism 
of misfolding (Conn et al., 2006a,b), mutant interactions 
with pharmacoperones (Ulloa-Aguirre et al., 2003) and the 
molecular basis of the dominant-negative effect (Conn et al., 
2006a,b). Recent studies (Janovick et al., 2007a) indicate that 
the mutant receptor that is already trapped in the ER can be 
freed by pharmacoperones – a surprising result that increases 
the potential therapeutic reach of this approach since pharma-
coperones do not need to be present at the moment of receptor 
synthesis.
PharmacoPerones
A pharmacoperone (from “pharmacological chaperone”) is a small 
molecule that enters cells and serves as a “molecular scaffold” to 
promote correct folding of otherwise-misfolded mutant proteins 
within the cell (Conn et al., 2002; Janovick et al., 2002). Misfolded 
proteins are often retained by the cellular QCS of the ER. For this 
reason, they do not reach their normal site of function (Bernier 
et al., 2004; Ulloa-Aguirre et al., 2004). This event may result in dis-
ease (Castro-Fernandez et al., 2005). Pharmacoperones can rescue 
misfolded receptor mutants and restore them to function, which 
is a potentially useful therapeutic approach when the target is a 
misfolded/misrouted protein. The literature was summarized for 
the GnRH and vasopressin type 2 (V2) receptors pharmacoperones 
with a view toward moving these compounds in vivo (Conn et al., 
2007). Science writers commenting on this approach (Hunter, 2004; 
Kresge, 2004) have observed that rescue with pharmacoperones is 
a viable “alternative (to gene therapy)” since it serves as a means 
of “skirting gene therapy to correct genetic defects.” This view is 
supported by the consideration that correction of defective protein 
folding appears significantly less challenging than replacement of 
a defective gene (or gene product) by a perfect one. One could, in 
fact, envision drugs given in a prophylactic manner (in vitamins, 
for example) that prevent the misfolding that leads to neurode-
generative disorders (Bellotti et al., 2007; Sun et al., 2007) and 
cataracts. In this regard, diseases may be prevented before clinical 
signs present themselves.
In addition to controlling the trafficking of mutants, this class 
of drugs may be useful for regulation of the PM expression of WT 
proteins since, for some PM receptors, a percentage of the nascent 
WT proteins also undergo misfolding (examples in; Conn et al., 
2006a) and are retained; this event may serve a cellular  regulatory 
( Petaja-Repo et al., 2000, 2001; Andersson et al., 2003; Cook et al., 
2003; Lu et al., 2003, 2004; Pietila et al., 2005). This suggests a level 
of post-translational control that may provide yet another level 
of potential therapeutic intervention (Ulloa-Aguirre et al., 2006): 
increasing the routing of WT GPCRs. In principle, the (endog-
enous) chaperoning system could mediate the fraction of the newly 
synthesized receptor that traverses to the PM and may contribute 
to the physiological changes in levels of GnRHR that are observed 
in different physiological settings (Marian et al., 1981).
PhysIologIcal sIgnIfIcance and ratIonal basIs of 
selectIon of the hgnrhr model
The GnRHR (also known as the luteinizing hormone releasing 
hormone receptor, LHRHR) resides in the gonadotrope cells of the 
pituitary and is responsible for producing responses to hypotha-
lamic GnRH, such as the releasing of the gonadotropins, luteinizing 
hormone (LH), and follicle stimulating hormone (FSH). When 
the function of this receptor is lost due to mutation, HH results.
Studies of the hGnRHR have led to useful drugs (agonists and 
antagonists) for the treatment of reproductive disorders and for 
cancer. Among the specific reasons for the view that the GnRH is an 
excellent model for these studies are the following considerations:
1. Gonadotropin-releasing hormone receptor itself is among 
the smallest GPCRs (328 amino acids in the human). There 
are technical advantages to small proteins since these require 
fewer primers for synthesis and for sequencing than do larger 
GPCRs (typically at least twice the size of the GnRHR), and 
there is less sequence length that might lead to random muta-
tion during the PCR process. DNA sequencing of mutants is 
also cheaper than for a larger protein. The size of the GnRHR 
means that there are fewer domains to consider in identifica-
tion of important structural motifs and because the size of 
hydrophobic domains is relatively constant even in different 
GPCRs (due to the relatively constant size needed to traverse 
the membrane), the ratio of these to non-hydrophobic regions 
is relatively high in the GnRHR due to the short NH
2
- and 
COOH-terminals. This promotes the interaction of small 
hydrophobic molecules that dissolve in the membrane.
2. The ligand (GnRH) itself and analogs are small and have good 
thermal and chemical stability which has led to the availabi-
lity of thousands of agonists and antagonists in the literature; 
these have been used for I125-radioligand assays and coupling 
of markers (colloidal gold, fluorescein, Texas Red).
3. The physiology of the system is well-characterized in many 
animal models and there is a broad basis for understanding 
processing differences now known to occur in closely related 
species (Knollman et al., 2005). We have taken advantage of the 
large number of GnRHR sequences that are available and been 
able to determine how changes in routing have been impac-
ted by sequence changes (i.e., natural mutation; Janovick et al., 
2006). Among primate receptors, for example, there are specia-
lizations that make these receptors able to decode frequency-
modulated, as well as amplitude-modulated, signals (Janovick 
et al., 2007b), and note structural changes among particular 
animals that appear to be explained by reproductive speciali-
zations (Knollman et al., 2005; Janovick et al., 2006, 2007b).
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Primary screen
The primary screen for pharmacoperones consists of measuring 
gain of activity in stable HeLa cells expressing the indicated mutant 
(hGnRHR[E90K]) under control of the tetracycline- controlled 
transactivator; the parent line was kindly supplied by Dr. Peter 
Seeburg (Max-Planck-Institut für Medizinische Forschung). 
Preparation of this mutant has been described (Janovick et al., 
2002). The DNA was inserted in the host cell according to pub-
lished methods (Krestel et al., 2001).
Negative screen
This assay is important in order to preclude moving “false” positives 
through the process. Stable cell lines which contain the tetracycline-
controlled transactivator, which shuts the gene off in the presence 
of this antibiotic are used (Krestel et al., 2001). There is literally 
no measurable expression, as assessed by protein expression or 
real-time PCR in the presence of tetracycline because the mutant 
GPCRs are under the control of this transactivator. Accordingly, 
cells cultured in the presence of tetracycline are substantially iden-
tical to the primary screen, but lack expression of the target gene 
and gene product. These cells (in the presence of tetracycline) will 
serve as an excellent negative control line. In both cases, coupling 
to second messenger is the measured endpoint.
Candidate compounds could also be screened in a radioligand 
assay (Janovick et al., 2007b) to determine if they compete with 
receptor agonists and antagonists. Other routine necessary negative 
controls, secondary screens, counter-screens and tests for specificity, 
range, linearity, accuracy, precision, limit of detection and limit of 
quantitation, robustness, reagent stability, and otherwise are not 
described in this manuscript due to space limitations.
We expect this assay to identify as “specific” other proteins that 
alter cellular machinery (e.g., ubiquitin ligases, heat shock proteins). 
It will be necessary to subject hits to a qualifying assay with a non-
GnRHR GPCR to exclude such false positives.
selectIon of the mutants
GnRHR mutant
The naturally occurring E90K mutation was selected. Modeling 
studies (Janovick et al., 2003a) for the hGnRHR and the data 
(Janovick et al., 2002, 2003a; Knollman et al., 2005) support the 
view that the E90–K121 salt bridge is a fundamental and evolution-
arily conserved determinant required for correct protein trafficking 
to the PM in all mammals examined. This bridge, linking TMS2 
to TMS3 is highly conserved in the GnRHR. E90 is conserved in 
mammals. Even in non-mammals, the TMS2–TMS3 salt bridge 
is needed and may have been formed by a D98–K121 bridge. D98 is 
absolutely conserved in all mammalian, reptilian, avian, and piscine 
GnRHRs sequenced to date. K121 is conserved in the same groups; 
in fruit flies, the residue is also a conservative change R121. A nega-
tive amino acid in TMS2 is also found in all other GPCRs (Ni and 
Lee, 2007) of the B-class, except the glucagon receptor. Because 
this salt bridge is a basic requirement for correct routing, E90K results 
in a routing defect in both mouse and human GnRHR (Brothers 
et al., 2004; Knollman et al., 2005; Janovick et al., 2007a). This 
leads to full, but rescuable, ER-retention (Brothers et al., 2004) 
and the predicted phenotype. While it is true that the orthologs of 
many misrouted human mutants are correctly routed in the mouse 
role (Conn et al., 2006a,b). Pharmacoperones can be used to 
increase PM expression of these, as well, and offer a therapeutic 
means of regulating these GPCRs. Accordingly, pharmacoperones 
can be viewed as agents that rescue misfolded mutants, but are 
also potentially able to increase the PM expression of WT proteins.
Problems wIth exIstIng PharmacoPerones and screenIng 
technIques
One problem with in vivo use of known pharmacoperones is that 
almost all existing ones for GPCRs are peptidomimetic antagonists 
directed against a site near that for the native ligand. This is because 
existing pharmacoperones, including In3 described below, were 
selected from assays that identified antagonists with target specifi-
city. In3 is highly specific for the GnRHR and was screened for more 
than 100 other structures, including α-adrenergics, β-adrenergics, 
adenosine receptor, bradykinin, CB1 and CB2, dopamine receptors, 
neurokinins, prostanoid receptors, serotonin receptors, somatosta-
tin, calcium, sodium, potassium channels, monoamine oxidases, 
and several phosphatases. There are a few exceptions to the use of 
antagonists-only as pharmacoperones: one agonist has been used for 
this purpose (Petaja-Repo et al., 2002) and one molecule has been 
used that does not appear to compete for the agonist or antagonist 
binding site (Janovick et al., 2009b). The latter was identified by our 
group, based on a fortuitous observation, not a screening process. 
The “overlap” of the majority of the pharmacoperones with the 
binding site means that there will likely be competition in vivo that 
will necessitate episodic administration and washout when used 
in vivo. From a therapeutic point of view, this presents a hurdle since 
oral dosing, while desirable (and possible with small molecules), 
is more difficult (there must be a washout period to prevent the 
pharmacoperone from competing with the endogenous ligand). It 
has certainly not been established that binding at or near the binding 
site of the natural ligand is a necessary pre-requisite for pharmaco-
perone activity and there is extant information to suggest otherwise 
(Conn and Janovick, 2009; Janovick et al., 2009a,b). This would, in 
fact, be an unexpected requirement since one could imagine phar-
macoperones that might stabilize the correctly routed form of the 
receptor and not show any antagonism. Accordingly, identification 
of non-antagonistic pharmacoperones is a reasonable goal.
Since most high throughput screens (HTS) approaches in the 
pharmaceutical industry revolved around assay models that iden-
tified agonists and antagonists, pharmacoperones that were not 
also agonists or antagonists would have been missed. Accordingly, 
rethinking the nature of the assay is important both to identify 
such overlooked structures, but also because they may prove to be 
more useful and therapeutically facile to use.
It is also worth noting that use of pharmacoperones drugs may 
unexpectedly alter physiological regulation. As an example, while 
correction of decreased LH in the male due to the E90K mutations 
in the GnRHR is likely to be straightforward, such a correction in 
females may be quite difficult, due to physiological cyclicity and 
elaborate feedback mechanisms.
new screenIng technIques
We have recently developed a new approach for the identification 
of pharmacoperones for hGnRHR mutants based on increase of 
activity of model mutants.
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used for RT to generate single strand DNA. Relative quantita-
tive standard curves for E90K and 18S RNA (the internal hou-
sekeeping gene product used to normalize the data or calculate 
a ratio between the gene of interest and the endogenous and 
unchanged standard) were generated by serial dilutions of 1:10 
of the RT product ranging from 1 to 10 ng. Ct values (Ct, the 
cycle threshold, is the cycle at which the fluorescence from a 
sample crosses the set threshold) were obtained, averaged, and 
converted to (logarithm) nanograms using the straight line 
extrapolation equation: ([ave Ct value] − b)/m; b = y − inter-
cept of standard curve line, m = slope of standard curve line). 
The ratio of E90K to 18S RNA was determined. The data 
(Figure 1) show that by 12 h in the presence of tetracycline, 
the RNA for hGnRHR[E90K] is no longer detectable.
– The rescuable GPCR mutant is under the control of tetra-
cycline and rescuable by pharmacoperone, In3. In this 
study (Figure 2), 20,000 stable cells/250 μl were  cultured 
(or rat; Knollman et al., 2005), E90K behaves similarly in mouse 
and human sequences (Knollman et al., 2005); the absence of K191 is 
without impact (Knollman et al., 2005). Further, in cell expression 
studies, mouse E90K, like the human mutant can be rescued by 
pharmacoperones (Knollman et al., 2005).
advantages and use of the stably transfected “tta” cells as 
an assay for PharmacoPerones
We use HeLa cells for the basis of our screen; such cells are human 
in origin and contain the same major (endogenous) chaperone 
proteins that are found in most human cells (Lievremont et al., 
1997; Feder and Hofmann, 1999; Ravindran et al., 2005); hGn-
RHR is processed, expressed, and coupled properly in these cells 
(Knollman and Conn, 2008) and they are adherent and well-
adapted to cell culture. A special feature of the cell lines used 
(Krestel et al., 2001) is that the GPCRs or GPCR mutants are 
expressed under the control of the tTA (tetracycline- controlled 
transactivator). In the absence of tetracycline, the GPCR is 
expressed. In the presence of tetracycline, the GPCR is not meas-
urably expressed. This model allows use of the GPCR to measure 
signal in the HTS (i.e., no tetracycline).
Cell culture and RNA extraction for real-time PCR
Stably transfected HeLa (tTA) cells were stably transfected with 
hE90K and then plated at 200,000 cells per well in a 6-well culture 
plate for extracting RNA. The cells were grown in DMEM/10% fetal 
calf serum, containing gentamicin, in a humidified atmosphere at 
37°C. To measure the time needed to “turn off” the gene, 1 μg/ml 
Tetracycline was added to each well and remained on the indicated 
cells for a maximum of 12 h. Cells were examined at differing times 
by dumping off medium, blotting, placing on ice, and washing two 
times with 2.5 ml 1× PBS (ice cold). Then 1 ml TRIZOL reagent is 
added per well and followed according to the manufacturer’s proto-
col. The cells were pipetted seven times through an RNase free pipet 
tip to lyse and transferred to a 1.5-ml RNase free centrifuge tube and 
frozen at −80°C until the total RNA was extracted. After extracting 
the RNA, it was dissolved in 25 μl diethylpyrocarbonate-treated water.
Real-time PCR
The TaqMan assay was used with the TaqMan PCR Core Reagent Kit 
with the ABI PRISM 7900HT Sequence Detection System (Applied 
Biosystems). The full length sequence of the human GnRH receptor 
was used to design the primers and probe for the real-time PCR 
assays for the mutant E90K. The TaqMan probe for the GnRHR 
mutant E90K was synthesized by Applied Biosystems; 5′-FAM-
CTCCCTGGCTATCACGAGGCCCCTAG-MGB-3′. For the internal 
control, 18S RNA, ABI’s MGB probe was used in the TaqMan assay.
The following evidence suggests that this screen will be extremely 
valuable:
– RNA for the GPCR mutant is expressed under the control 
of tetracycline. Stable cells were cultured in the presence of 
tetracycline for varying amounts of time in order to show a 
time course for complete extinction of expression of the E90K 
mutant. Total RNA was extracted from the cells followed by 
reverse transcription (RT) for obtaining single strand DNA 
for use in real-time PCR. One microgram of total RNA was 
FiGurE 1 | Tetracycline inhibits accumulation of E90K mrNA (normalized 
with 18S rNA) and assessed by real-time PCr.
FiGurE 2 | Loss of iP production (in the presence of tetracycline) in stably 
transfected cells with or without in3 treatment shows that expression of 
the (rescued) mutant protein is under control of this antibiotic.
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FiGurE 3 | Well-by-well iP stimulation in response to a GnrH agonist, following rescue of mutant E90K by maximum, EC80, or no pharmacoperone (in3). 
Data is graphed by row, then column. The upper graphic shows the absence of tetracycline; the lower graphic shows the presence of tetracycline. Note that the 
y-axis differs.
in the presence of increasing concentrations of tetra-
cycline, which was continuously present thereafter, for a 
total of 48 h. Cells (48-well plates) were treated with or 
without pharmacoperone In3 (“In3” is our lab name for 
pharmacoperone, [(2S)-2-[5-[2-(2-azabicyclo[2.2.2]oct-
2-yl)-1,1-dimethyl-2-oxoethyl]-2-(3,5-dimethylphenyl)-
1H-indol-3-yl]-N-(2-pyridin-4-ylethyl)propan-1-amine]), 
which was originally developed as a specific antagonist of 
the GnRHR (Ashton et al., 2001). The pharmacoperone is 
then removed and cells labeled with 3H-inositol for 18 h 
and then stimulated with 10−6 M Buserelin and total ino-
sitol phosphate (IP) was then measured by ion exchange 
chromatography (Huckle and Conn, 1987). These studies 
show that stimulation of IP production in response to 
the GnRHR agonist, Buserelin, is lost in the presence of 
tetracycline and that the known pharmacoperone In3 can 
rescue this mutant with an excellent signal-to-noise ratio 
(Figure 2). The IP assay, using disposable columns, resin, 
and a skilled operator can conveniently assay 1,000 samples 
in a day.
– In order to perform (i) a preliminary assessment of the assay 
performance and (ii) demonstrate the ability to perform the 
assay in 96-well plates, the study, shown in Figure 3, was per-
formed (all wells in 1% DMSO). This study also (iii) shows 
the utility of cells treated with tetracycline (which extin-
guishes expression of the mutant hGnRHR gene) as a nega-
tive screen. The upper frame in Figure 3 demonstrates that 
positives can be identified with a good sensitivity and high 
signal-to-noise ratio, with minimal wall effects and good 
reproducibility.
In this study, stable cells were cultured in the absence (upper 
frame) or presence (lower frame) of tetracycline which was 
continuously present thereafter, as described above (“b”). 
Pharmacoperone was added at the indicated concentrations in 
1% DMSO final. Total IP was measured. The x-axis was numeri-
cally compressed for this image and is labeled 0–32. There are 
32 (interspersed) wells of either DMSO only (DMSO control, 
green), an EC
80
 dose of pharmacoperone In3 in 1% DMSO (red) 
or a saturating dose of In3 in 1% DMSO (black); 3 × 32 = 96. 
Every third well contained DMSO, EC
80
 dose of pharmacoperone 
In3, or a saturating dose of pharmacoperone In3 so that the next 
row of wells contained the same treatment diagonally. In Figure 
3, rescue was performed on cells in the absence of tetracycline 
(which allows the receptor mutant to be expressed). This would 
serve as the primary screen.
In the lower image of Figure 3, tetracycline was present and, 
accordingly, the gene for the hGnRHR mutant was shut off. This 
would serve as a negative screen for agents that affect their action 
by some means other than through the hGnRHR. In that image, 
there is no significant or reproducible response difference between 
cells that have been incubated with pharmacoperone In3 because 
the gene for the mutant receptor is not expressed. Agents that act 
through a means other than the hGnRHR would be expected to 
still respond since, other than lacking the hGnRHR (mutant), the 
cells are otherwise identical.
Figure 4 shows the same data expressed in a “column then row” 
format instead of the “row then column” format above. This shows, 
by inspection, the absence of wall effects. These are aberrant effects 
sometimes observed for cells plated in a well adjacent to an edge 
or corner of a culture plate.
conclusIon
While pharmacoperones may also be agonists or antagonists and 
are frequently selected from HTS assays for such drugs, this is 
not a requirement. Pharmacoperones have the potential to over-
ride normal physiological levels of receptors and other proteins. 
This approach may result in altered regulation and may change 
the number of receptors present at the PM by rescuing misfolded 
mutants or increasing PM expression of fractionally expressed WT 
receptors. Accordingly, the screening approach we describe is useful 
for treatment of diseases in which the underlying caused is loss of 
receptors due to mutation and subsequent misrouting (retention 
in the ER). This is a novel screen that may lead to identification 
of pharmacoperones that do not compete with the endogenous 
ligands, since these agents may have a therapeutic advantage. In 
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